Literature DB >> 25371860

Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review.

Pablo S Rivadeneira1, Claude H Moog2, Guy-Bart Stan3, Cecile Brunet4, François Raffi4, Virginie Ferré4, Vicente Costanza5, Marie J Mhawej2, Federico Biafore6, Djomangan A Ouattara2, Damien Ernst7, Raphael Fonteneau7, Xiaohua Xia8.   

Abstract

This review shows the potential ground-breaking impact that mathematical tools may have in the analysis and the understanding of the HIV dynamics. In the first part, early diagnosis of immunological failure is inferred from the estimation of certain parameters of a mathematical model of the HIV infection dynamics. This method is supported by clinical research results from an original clinical trial: data just after 1 month following therapy initiation are used to carry out the model identification. The diagnosis is shown to be consistent with results from monitoring of the patients after 6 months. In the second part of this review, prospective research results are given for the design of individual anti-HIV treatments optimizing the recovery of the immune system and minimizing side effects. In this respect, two methods are discussed. The first one combines HIV population dynamics with pharmacokinetics and pharmacodynamics models to generate drug treatments using impulsive control systems. The second one is based on optimal control theory and uses a recently published differential equation to model the side effects produced by highly active antiretroviral therapy therapies. The main advantage of these revisited methods is that the drug treatment is computed directly in amounts of drugs, which is easier to interpret by physicians and patients.

Entities:  

Keywords:  AIDS; HIV; aid for diagnosis; apoptosis; dynamical systems; modeling; nonlinear control; pharmacodynamics; pharmacokinetics

Year:  2014        PMID: 25371860      PMCID: PMC4215334          DOI: 10.1089/biores.2014.0024

Source DB:  PubMed          Journal:  Biores Open Access        ISSN: 2164-7844


  26 in total

1.  Amplicor HIV monitor, NASBA HIV-1 RNA QT and quantiplex HIV RNA version 2.0 viral load assays: a Canadian evaluation.

Authors:  I T Prud'homme; J E Kim; R G Pilon; T Minkus; N Hawley-Foss; W Cameron; E W Rud
Journal:  J Clin Virol       Date:  1998-12       Impact factor: 3.168

2.  Dynamic multidrug therapies for hiv: optimal and sti control approaches.

Authors:  B M Adams; H T Banks; Hee-Dae Kwon; Hien T Tran
Journal:  Math Biosci Eng       Date:  2004-09       Impact factor: 2.080

3.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

4.  Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens.

Authors:  Rick Galli; Linda Merrick; Michel Friesenhahn; Rainer Ziermann
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

5.  TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay Quantification of HIV-1 RNA viral load in breast milk.

Authors:  Kiersten Israel-Ballard; Rainer Ziermann; Christian Leutenegger; James Di Canzio; Kimmy Leung; Lynn Strom; Barbara Abrams; Caroline Chantry
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

6.  A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.

Authors:  Martin Markowitz; Michael Louie; Arlene Hurley; Eugene Sun; Michele Di Mascio; Alan S Perelson; David D Ho
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4.

Authors:  G Herbein; U Mahlknecht; F Batliwalla; P Gregersen; T Pappas; J Butler; W A O'Brien; E Verdin
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

9.  When to initiate HIV therapy: a control theoretic approach.

Authors:  Annah M Jeffrey; Xiaohua Xia; Ian K Craig
Journal:  IEEE Trans Biomed Eng       Date:  2003-11       Impact factor: 4.538

Review 10.  Apoptosis of uninfected cells induced by HIV envelope glycoproteins.

Authors:  Barbara Ahr; Véronique Robert-Hebmann; Christian Devaux; Martine Biard-Piechaczyk
Journal:  Retrovirology       Date:  2004-06-23       Impact factor: 4.602

View more
  3 in total

Review 1.  Modeling Kick-Kill Strategies toward HIV Cure.

Authors:  Esteban A Hernandez-Vargas
Journal:  Front Immunol       Date:  2017-08-28       Impact factor: 7.561

2.  In-host Mathematical Modelling of COVID-19 in Humans.

Authors:  Esteban A Hernandez-Vargas; Jorge X Velasco-Hernandez
Journal:  Annu Rev Control       Date:  2020-09-30       Impact factor: 6.091

3.  Robust adaptive Lyapunov-based control of hepatitis B infection.

Authors:  Omid Aghajanzadeh; Mojtaba Sharifi; Shabnam Tashakori; Hassan Zohoor
Journal:  IET Syst Biol       Date:  2018-04       Impact factor: 1.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.